Combined omeprazole–amoxicillin regimen (OA regimen)

The combined omeprazole–amoxicillin regimen is a therapeutic drug combination primarily utilized for the eradication of Helicobacter pylori, a bacterium associated with gastritis and peptic ulcer disease (StatPearls, 2023). This regimen is not a single biological target but rather a pharmacological strategy that leverages the synergistic effects of a proton pump inhibitor (PPI) and a bactericidal antibiotic. Omeprazole functions by inhibiting the gastric H+/K+-ATPase, thereby increasing the intragastric pH (PubMed, PMID: 11051351). This pH elevation is critical as it prevents the degradation of amoxicillin in the acidic stomach environment and promotes H. pylori into a replicative state, making the bacteria more susceptible to the cell wall-inhibiting effects of amoxicillin (NIH, 2022). While historically used in dual therapy, it is often integrated into triple or quadruple therapy protocols to improve eradication rates and combat antibiotic resistance (American College of Gastroenterology, 2017). The efficacy of this combination depends on maintaining a high intragastric pH to optimize the antibiotic's pharmacodynamics.

Other names

Omeprazole-amoxicillin dual therapyOA therapyHigh-dose dual therapy (HDDT)PPI-amoxicillin combination

The regimen works through a synergistic mechanism: Omeprazole covalently binds to the H+/K+-ATPase enzyme (proton pump) in gastric parietal cells, suppressing the final step of acid production. This increase in gastric pH (typically >4.0) stabilizes amoxicillin, which is otherwise acid-labile, and increases the fraction of H. pylori in the growth phase. Amoxicillin then acts by binding to penicillin-binding proteins (PBPs), inhibiting the cross-linking of peptidoglycan in the bacterial cell wall, leading to bacterial lysis and death.